Status:
UNKNOWN
Dose-Ranging Efficacy Study of Topical NEOSH101 to Treat Male Pattern Hair Loss
Lead Sponsor:
Neosil, Inc.
Conditions:
Androgenetic Alopecia
Eligibility:
MALE
18-49 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to evaluate the safety and efficacy of three doses of topical NEOSH101 applied once-daily (qd) for 16 weeks in men with thinning hair in the top and center of the scalp (N...
Eligibility Criteria
Inclusion
- Men, aged 18 to 49 years, in general good health
- Norwood/Hamilton grades III - IV androgenetic alopecia, with thinning hair in the vertex area
Exclusion
- Concomitant dermatologic or medical condition(s) which may interfere with the investigator's ability to evaluate the subject's response to the study drug
- Treatment with a systemic or locally acting medication which may interfere with the study objectives, such as minoxidil treatment in the 6 months prior to study day 1, finasteride treatment in the 12 months prior to study day 1, or treatment with other investigational hair growth products in the 6 months prior to study day 1
Key Trial Info
Start Date :
May 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
140 Patients enrolled
Trial Details
Trial ID
NCT00471510
Start Date
May 1 2007
Last Update
May 20 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
bioskin Institute for Dermatological Research and Development GmbH
Hamburg, Germany, 20095